{"id":64334,"date":"2026-04-30T15:16:05","date_gmt":"2026-04-30T07:16:05","guid":{"rendered":"https:\/\/flcube.com\/?p=64334"},"modified":"2026-04-30T15:16:06","modified_gmt":"2026-04-30T07:16:06","slug":"innovent-biologics-reports-50-q1-revenue-growth-to-555m-driven-by-nrdl-tkis-and-integrated-portfolio-strength","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64334","title":{"rendered":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength"},"content":{"rendered":"\n<p><strong>Innovent Biologics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) reported <strong>Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million)<\/strong>, representing <strong>50% year-over-year (YOY) growth<\/strong>. The robust performance was driven by rapid uptake of <strong>five newly reimbursed tyrosine kinase inhibitors (TKIs)<\/strong> and strong momentum from the company&#8217;s <strong>integrated product portfolio<\/strong>, including core assets <strong>Xinermei (mazdutide)<\/strong>, <strong>Xinbiyue (tafolecimab)<\/strong>, and <strong>Xinbimin (teprotumumab N01)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights-q1-2026\">Financial Highlights \u2013 Q1 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Product Sales<\/strong><\/td><td>RMB 3.8B (USD 555M)<\/td><td>+50%<\/td><\/tr><tr><td><strong>Growth Drivers<\/strong><\/td><td>NRDL-reimbursed TKIs + integrated portfolio<\/td><td>N\/A<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Oncology leadership with expansion into CVM, autoimmune, and ophthalmology<\/td><td>N\/A<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-portfolio-performance-drivers\">Portfolio Performance Drivers<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-nrdl-reimbursed-tkis\">NRDL-Reimbursed TKIs<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Five tyrosine kinase inhibitors<\/strong> newly added to <strong>National Reimbursement Drug List (NRDL)<\/strong><\/li>\n\n\n\n<li><strong>Rapid market uptake<\/strong> demonstrating immediate commercial impact of reimbursement inclusion<\/li>\n\n\n\n<li><strong>Oncology leadership<\/strong> increasingly evident through broad TKI portfolio penetration<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-integrated-product-portfolio\">Integrated Product Portfolio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Xinermei (mazdutide)<\/strong>: GLP-1\/GCG dual agonist showing outstanding performance in metabolic disease segment<\/li>\n\n\n\n<li><strong>Xinbiyue (tafolecimab)<\/strong>: PD-L1\/VEGF bispecific antibody contributing to oncology-immunology crossover success<\/li>\n\n\n\n<li><strong>Xinbimin (teprotumumab N01)<\/strong>: IGF-1R inhibitor for thyroid eye disease expanding into ophthalmology indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-late-stage-pipeline-advancement\">Late-Stage Pipeline Advancement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Mechanism<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>IBI363<\/strong><\/td><td>PD-1\/IL-2\u03b1-biased bispecific antibody<\/td><td>Global multicenter Phase III<\/td><\/tr><tr><td><strong>IBI343<\/strong><\/td><td>CLDN18.2 antibody-drug conjugate (ADC)<\/td><td>Global multicenter Phase III<\/td><\/tr><tr><td><strong>IBI324<\/strong><\/td><td>VEGF\/ANG2 bispecific antibody<\/td><td>Advancing toward global multicenter Phase III<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-significance\">Pipeline Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Ambition<\/strong>: All three high-potential molecules progressing through international clinical development programs<\/li>\n\n\n\n<li><strong>Target Diversity<\/strong>: Spanning immuno-oncology (IBI363), targeted ADC therapy (IBI343), and anti-angiogenesis (IBI324)<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Phase III assets represent next-generation revenue drivers beyond current portfolio<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-area-expansion-strategy\">Therapeutic Area Expansion Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Area<\/th><th>Strategic Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncology<\/strong><\/td><td>Core strength with TKIs, bispecifics, and ADCs across multiple targets<\/td><\/tr><tr><td><strong>Cardiovascular &amp; Metabolic (CVM)<\/strong><\/td><td>Mazdutide leading expansion into obesity\/diabetes markets<\/td><\/tr><tr><td><strong>Autoimmune Diseases<\/strong><\/td><td>Early-stage innovation leveraging immunology platform capabilities<\/td><\/tr><tr><td><strong>Ophthalmology<\/strong><\/td><td>Teprotumumab N01 establishing presence in specialized eye disease segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-outlook\">Strategic Implications &amp; Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Leverage<\/strong>: NRDL inclusion strategy proving highly effective for rapid commercial scale-up in China<\/li>\n\n\n\n<li><strong>Portfolio Diversification<\/strong>: Successful expansion beyond oncology creates multiple growth vectors and reduces therapeutic concentration risk<\/li>\n\n\n\n<li><strong>Global Development Capability<\/strong>: Advanced pipeline demonstrates sophisticated clinical trial execution across international sites<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Strong early-stage assets ensure sustainable long-term growth beyond current commercial products<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Integrated approach combining domestic commercial strength with global development ambitions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, product adoption rates, clinical development timelines, and commercial potential. Actual results may differ due to risks including market competition, regulatory decisions, reimbursement dynamics, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026043000286_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026043000286_c.\"><\/object><a id=\"wp-block-file--media-c347aba4-afbb-4266-8f25-2f12c095e224\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026043000286_c.pdf\">2026043000286_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026043000286_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c347aba4-afbb-4266-8f25-2f12c095e224\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64336,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,910,198],"class_list":["post-64334","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company&#039;s integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64334\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company&#039;s integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64334\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T07:16:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T07:16:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength\",\"datePublished\":\"2026-04-30T07:16:05+00:00\",\"dateModified\":\"2026-04-30T07:16:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3005.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64334#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64334\",\"name\":\"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3005.webp\",\"datePublished\":\"2026-04-30T07:16:05+00:00\",\"dateModified\":\"2026-04-30T07:16:06+00:00\",\"description\":\"Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company's integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64334\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64334#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company's integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64334","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength","og_description":"Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company's integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).","og_url":"https:\/\/flcube.com\/?p=64334","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T07:16:05+00:00","article_modified_time":"2026-04-30T07:16:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64334#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64334"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength","datePublished":"2026-04-30T07:16:05+00:00","dateModified":"2026-04-30T07:16:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64334"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64334#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp","keywords":["Finanical Reports","HKG: 1801","Innovent Biologics"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64334#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64334","url":"https:\/\/flcube.com\/?p=64334","name":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64334#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64334#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp","datePublished":"2026-04-30T07:16:05+00:00","dateModified":"2026-04-30T07:16:06+00:00","description":"Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company's integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64334#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64334"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64334#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp","width":1080,"height":608,"caption":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64334#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64334"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64334\/revisions"}],"predecessor-version":[{"id":64337,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64334\/revisions\/64337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64336"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}